Return to homepagePandemic Pact

Methyltransferase inhibitors for treatment of COVID19

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2023

  • Known Financial Commitments (USD)

    $159,635.4

  • Funder

    ERC

  • Principal Investigator

    Andreas PICHLMAIR

  • Research Location

    Germany

  • Lead Research Institution

    Technical University of Munich

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Our IP secured drug DZNep is effective in treating SARS-CoV-2 infections in preclinical disease models and uniquely suppresses virus growth, triggers the innate immunity and facilitates tissue regeneration. The ERC-PoC will enable the transition from preclinical to clinical research.